Novo expands its GLP-1 partnership with Humana's CenterWell Pharmacy

Novo Nordisk has expanded its arrangement with Humana's CenterWell Pharmacy, adding prescription fulfillment and home delivery of Wegovy for patients who pay out of pocket through the company's direct-to-patient NovoCare program ^[1]. The expansion, reported in late April, builds on telehealth partnerships Novo announced weeks earlier and adds another link in the supply chain meant to get the drug to patients without going through a traditional retail pharmacy counter ^[1].

Under the arrangement, telehealth providers Hims & Hers Health, LifeMD, and Ro work directly with NovoCare to write prescriptions for self-pay Wegovy patients, while CenterWell handles the back-end work of filling those prescriptions and shipping them to patients' homes ^[1]. NovoCare Pharmacy launched in March, offering Wegovy to self-paying patients for $499 a month; that same price is also available to eligible patients who fill their prescription at a local pharmacy instead of through the direct-to-patient channel ^[1].

The distribution expansion comes as Novo Nordisk and rival Eli Lilly compete on price and access for their GLP-1 drugs. Eli Lilly has been selling higher-dose Zepbound vials, 7.5 milligrams and 10 milligrams, for $499 at first fill through its own direct-to-consumer platform, with the price rising to $599 and $699 for subsequent fills of those doses ^[1]. Separately, CVS Caremark, the country's largest pharmacy benefit manager, named Wegovy the preferred GLP-1 medicine on its largest commercial template formularies effective July 1, a shift a CVS spokesperson attributed to Novo securing a lower net price than Zepbound on those formularies ^[1].

The commercial moves are unfolding alongside new clinical data. A trial published in the New England Journal of Medicine on April 30 found Wegovy reduced liver inflammation in 63% of patients with the liver disease MASH, compared with 34.3% of patients on a placebo, and improved liver fibrosis in 37% of patients versus 22.4% on placebo ^[1].

Why it matters for patients

For people paying out of pocket for Wegovy, the CenterWell expansion is mainly a logistics change: it adds a second, home-delivery-focused fulfillment path alongside retail pharmacies, without changing the $499 self-pay price already available through NovoCare ^[1]. Patients using telehealth services like Hims & Hers, LifeMD, or Ro to get a Wegovy prescription may now have their orders filled and shipped through CenterWell rather than a different pharmacy partner ^[1].

The broader competitive picture also matters for cost. With CVS Caremark now favoring Wegovy on its biggest commercial formularies starting in July, some patients with insurance through CVS Caremark-managed plans may find Wegovy easier to get covered than Zepbound, depending on their specific plan ^[1]. Patients considering Zepbound's direct-to-consumer pricing should note Lilly's cash price rises after the first fill of the higher-dose vials, from $499 to $599 or $699 ^[1].

The new liver-disease data add another data point for patients with MASH who may be weighing GLP-1 treatment, though the sources here do not detail whether or how quickly this evidence could affect insurance coverage or FDA-approved uses ^[1].

What happens next

CVS Caremark's formulary change favoring Wegovy takes effect July 1 ^[1]. Beyond that date, the sources do not specify further timelines for the CenterWell fulfillment expansion or how the shifting formulary and pricing landscape between Novo Nordisk and Eli Lilly will develop.